Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469819 · ClinicalTrials.gov registry record · Phase 2
Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation
A Phase 2 study, sponsored by Texas Tech University Health Sciences Center, El Paso.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT01469819 is a Phase 2 study that has completed, run by Texas Tech University Health Sciences Center, El Paso. The registered enrollment target is 37 participants.
The verdict
NCT01469819, a Phase 2 study, has completed, sponsored by Texas Tech University Health Sciences Center, El Paso.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation. To be able to measure the time difference in the duration of transit of the FDA approved SmartPill capsule in all segments of gastrointestinal (GI) tract before and after exposure to lubiprostone. The investigators anticipate to capture the possibility to reduce/eliminate the small intestinal bacterial overgrowth in chronically constipated patients after administration of study drug- lubiprostone.
Interventions
- DRUG Lubiprostone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01469819
The ClinicalTrials.gov registry entry for NCT01469819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Tech University Health Sciences Center, El Paso, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lubiprostone is the first listed.
NCT01469819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01469819 about?
NCT01469819 is a clinical study titled "Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation". The purpose of this study is to determine if lubiprostone may change the rate of movement of food and activities in the stomach and intestines in subjects whose gastrointestinal (GI) tract is slower due to constipation. To be able to measure the time difference in the duration of transit of the FDA...
What is the current status of trial NCT01469819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2012-06. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01469819?
The interventions under investigation include: Lubiprostone (DRUG).
Who is sponsoring clinical trial NCT01469819?
This trial is sponsored by Texas Tech University Health Sciences Center, El Paso, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.